bioAffinity Technologies (BIAF) Set to Post Quarterly Earnings on Wednesday

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect bioAffinity Technologies to announce earnings of ($31.50) per share and revenue of $1.91 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 7:00 AM ET.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($31.50) by $25.61. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.91 million. bioAffinity Technologies had a negative net margin of 278.90% and a negative return on equity of 293.44%.

bioAffinity Technologies Stock Performance

Shares of NASDAQ:BIAF opened at $2.00 on Tuesday. The firm has a 50 day simple moving average of $5.10 and a 200 day simple moving average of $18.16. bioAffinity Technologies has a 52 week low of $1.96 and a 52 week high of $80.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.41 and a current ratio of 1.51.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wall Street Zen cut shares of bioAffinity Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, bioAffinity Technologies currently has a consensus rating of “Sell”.

Get Our Latest Report on bioAffinity Technologies

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection. The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services.

Featured Stories

Earnings History for bioAffinity Technologies (NASDAQ:BIAF)

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.